FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with Votrient should only be started by a doctor who has experience in giving anticancer medicines.
Estonian: Ravi Votrientiga tohib alustada üksnes vähiravimite kasutamises kogenud arst.
English: Votrient was originally given ‘conditional approval' because there was more evidence to come about the medicine, in particular in the treatment of renal cell carcinoma.
Estonian: Votrientile anti müügiluba esialgu tingimuslikult, sest ravimi ja eelkõige selle kasutamise kohta neerurakk-kartsinoomi ravis oodati täiendavaid andmeid.
English: The CHMP considered that Votrient has been shown to be an effective medicine for patients with advanced renal cell carcinoma and soft-tissue sarcoma, with a clinically relevant improvement in progression-free survival.
Estonian: Inimravimite komitee leidis, et Votrient osutus kaugelearenenud neerurakk-kartsinoomi ja pehmekoesarkoomi ravis tõhusaks, parandades patsientide progressioonivaba elulemust kliiniliselt olulisel määral.
English: What benefit has Votrient shown during the studies?
Estonian: Milles seisneb uuringute põhjal Votrienti kasulikkus?
English: It is used in patients who have not received any previous treatment or in patients who have already been treated for their advanced disease with anticancer medicines called ‘cytokines'.
Estonian: Seda kasutatakse varem ravimata patsientidel ja patsientidel, kelle kaugelearenenud haigust on ravitud vähiravimite tsütokiinidega.
English: • advanced renal cell carcinoma, a type of kidney cancer.
Estonian: • kaugelearenenud neerurakk-kartsinoom (teatud neeruvähiliik).
English: The active substance in Votrient, pazopanib, is a protein kinase inhibitor.
Estonian: Votrienti toimeaine pasopaniib on proteiinkinaasiinhibiitor ehk aine, mis blokeerib ensüüme proteiinkinaase.
English: How is Votrient used?
Estonian: Kuidas Votrienti kasutatakse?
English: What is Votrient used for?
Estonian: Milleks Votrienti kasutatakse?
English: Votrient was also more effective than placebo at treating soft-tissue sarcoma.
Estonian: Votrient oli ka pehmekoesarkoomi ravis efektiivsem kui platseebo.
English: How does Votrient work?
Estonian: Kuidas Votrient toimib?
English: How has Votrient been studied?
Estonian: Kuidas Votrienti uuriti?
English: • certain forms of soft-tissue sarcoma, a type of cancer that develops from the soft, supporting tissues of the body.
Estonian: • kaugelearenenud pehmekoesarkoom- pehmete tugikudede teatud vähiliik.
English: Votrient was more effective than placebo at treating advanced renal cell carcinoma.
Estonian: Votrient oli kaugelearenenud neerurakk-kartsinoomi ravis platseebost efektiivsem.
English: The medicine can only be obtained with a prescription.
Estonian: Votrient on retseptiravim.
English: The full EPAR for Levetiracetam Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Levetiracetam Accordi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: It is available as tablets (250 mg, 500 mg, 750 mg and 1,000 mg).
Estonian: Ravimit turustatakse tablettidena (250 mg, 500 mg, 750 mg ja 1000 mg).
English: The European Commission granted a marketing authorisation valid throughout the European Union for Levetiracetam Accord on3 October 2011.
Estonian: Euroopa Komisjon andis Levetiracetam Accordi müügiloa, mis kehtib kogu Euroopa Liidus, 3. oktoobril
English: What measures are being taken to ensure the safe and effective use of Levetiracetam Accord?
Estonian: Mis meetmed võetakse, et tagada Levetiracetam Accordi ohutu ja efektiivne kasutamine?
English: This is a type of epilepsy where excessive electrical activity in one side of the brain causes symptoms such as sudden, jerky movements of one part of the body, distorted hearing, sense of smell or vision, numbness, or a sudden sense of fear.
Estonian: See on epilepsia vorm, kus aju ühe poolkera elektriline liigtalitlus tekitab selliseid sümptomeid nagu ühe kehapoole järsud tõmblused, kuulmis-, haistmis- või nägemishäired, tuimus või äkiline hirmutunne.
English: Levetiracetam Accord levetiracetam
Estonian: Levetiracetam Accord levetiratsetaam
English: Secondary generalisation occurs when the overactivity later reaches the whole brain.
Estonian: Sekundaarse generalisatsiooni korral levib liigtalitlus edasi kogu ajule.
English: This helps Levetiracetam Accord to stabilise electrical activity in the brain and prevent seizures.
Estonian: See aitab Levetiracetam Accordil stabiliseerida aju elektrilist talitlust ning ennetada krampe.
English: The exact way in which levetiracetam works is unclear but it attaches to a protein called synaptic vesicle protein 2A, which is involved in the release of chemical messengers from nerve cells.
Estonian: Levetiratsetaami täpne toimemehhanism ei ole teada, kuid ravim seondub sünapsipõiekeste valguga 2A, mis osaleb närvirakkudest keemiliste virgatsainete vabastamisel.
English: For more information about treatment with Levetiracetam Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Levetiracetam Accordiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: The Committee recommended that Levetiracetam Accord be given marketing authorisation.
Estonian: Komitee soovitas anda ravimi müügiloa.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Levetiracetam Accord.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Levetiracetam Accord have been included in the summary of product characteristics and the package leaflet.
Estonian: Levetiracetam Accordi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Levetiracetam Accord tablets are swallowed with liquid.
Estonian: Levetiracetam Accordi tabletid neelatakse koos vedelikuga.
English: • primary generalised tonic-clonic seizures (major fits, including loss of consciousness) in patients from 12 years of age with idiopathic generalised epilepsy (the type of epilepsy that is thought to be inherited).
Estonian: • primaarsed generaliseerunud toonilised-kloonilised episoodid (rasked epilepsiaepisoodid, millega kaasneb ka teadvusekaotus) vähemalt 12-aastastel patsientidel, kellel on idiopaatiline generaliseerunud epilepsia (epilepsia liik, mille tekkepõhjust peetakse geneetiliseks).
English: • myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in patients from 12 years of age with juvenile myoclonic epilepsy;
Estonian: • müokloonilised episoodid (lühiajalised šokitaolised lihaste või lihaserühmade tõmblused) vähemalt 12-aastastel patsientidel, kellel on noorukiea müoklooniline epilepsia;
English: Therefore, the CHMP's view was that, as for Keppra, the benefit outweighs the identified risk.
Estonian: Seetõttu arvas inimravimite komitee, et nagu ka Keppra korral, ületab Levetiracetam Accordi kasulikkus sellega kaasnevad riskid.
English: The CHMP concluded that, in accordance with EU requirements, Levetiracetam Accord has been shown to have comparable quality and to be bioequivalent to Keppra.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Levetiracetam Accord võrdväärne kvaliteet ja bioekvivalentsus ravimiga Keppra.
English: This means that Levetiracetam Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called Keppra.
Estonian: See tähendab, et Levetiracetam Accord on sarnane võrdlusravimiga Keppra, millel juba on Euroopa Liidus müügiluba.
English: Because Levetiracetam Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Levetiracetam Accord on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Levetiracetam Accord can also be used as an add-on to other epilepsy medicines to treat:
Estonian: Levetiracetam Accordi tohib kasutada ka teiste epilepsiaravimite lisaravimina, et ravida järgmisi haigusseisundeid:
English: When Levetiracetam Accord is added to another epilepsy treatment, the starting dose in patients over 12 years weighing more than 50 kg is 500 mg twice a day.
Estonian: Levetiracetam Accordi lisamisel teisele epilepsiaravimile vähemalt 12-aastastel patsientidel kehamassiga üle 50 kg on algannus 500 mg kaks korda ööpäevas.
English: Levetiracetam Accord can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation.
Estonian: Levetiracetam Accordi tohib kasutada ainsa ravimina vähemalt 16-aastastel epilepsia esmadiagnoosiga patsientidel, et ravida sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalseid episoode.
English: For patients weighing less than 50 kg, the dose depends on body weight.
Estonian: Alla 50 kg kehamassiga patsientide soovitatav annus oleneb kehamassist.
English: Patients who cannot take tablets should be given a solution containing levetiracetam.
Estonian: Neelamisraskustega patsientidele tuleb anda levetiratsetaami sisaldavat lahust.
English: Because Levetiracetam Accord is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Keppra.
Estonian: Et Levetiracetam Accord on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Levetiracetam Accordi bioekvivalentsust võrdlusravimiga Keppra.
English: Levetiracetam Accord is a medicine that contains the active substance levetiracetam.
Estonian: Levetiracetam Accord on ravim, mis sisaldab toimeainena levetiratsetaami.
English: This is a summary of the European public assessment report (EPAR) for Levetiracetam Accord.
Estonian: See on ravimi Levetiracetam Accord Euroopa avaliku hindamisaruande kokkuvõte.
English: • partial-onset seizures with or without generalisation in patients from 1 month of age;
Estonian: • sekundaarse generalisatsiooniga või sekundaarse generalisatsioonita partsiaalsed episoodid vähemalt 1-kuulistel patsientidel;
English: The daily dose can be increased up to 1,500 mg twice a day.
Estonian: Ööpäevast annust tohib suurendada 1500 mg-ni kaks korda ööpäevas.
English: Levetiracetam Accord is a ‘generic medicine'.
Estonian: Levetiracetam Accord on geneeriline ravim.
English: When Levetiracetam Accord is used on its own, the starting dose is 250 mg twice a day, increasing two weeks later to 500 mg twice a day.
Estonian: Levetiracetam Accordi kasutamisel ainsa ravimina on algannus 250 mg kaks korda ööpäevas; seda suurendatakse kahe nädala pärast 500 mg-ni kaks korda ööpäevas.
English: Why has Levetiracetam Accord been approved?
Estonian: Miks Levetiracetam Accord heaks kiideti?
English: How has Levetiracetam Accord been studied?
Estonian: Kuidas Levetiracetam Accordi uuriti?
English: What are the benefits and risks of Levetiracetam Accord?
Estonian: Milles seisneb Levetiracetam Accordi kasulikkus ja mis riskid ravimiga kaasnevad?
English: What is Levetiracetam Accord?
Estonian: Mis on Levetiracetam Accord?
English: How is Levetiracetam Accord used?
Estonian: Kuidas Levetiracetam Accordi kasutatakse?
English: Other information about Levetiracetam Accord
Estonian: Muu teave Levetiracetam Accordi kohta
English: What is Levetiracetam Accord used for?
Estonian: Milleks Levetiracetam Accordi kasutatakse?
English: The teratological importance of these findings is unclear.
Estonian: Nende tulemuste teratoloogiline olulisus on ebaselge.
English: Your doctor may have to adjust your dose.
Estonian: Teie arst võib teie annust kohandada.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/18/1269/001
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/18/1269/001
English: Other medicines and Alpivab
Estonian: Muud ravimid ja Alpivab
English: Risk of bacterial infections
Estonian: Bakterinfektsioonide risk
English: Placebo n=100
Estonian: Platseebo n = 100
English: Key efficacy results are presented in Table 4.
Estonian: Peamised efektiivsustulemused on tabelis 4.
English: E-mail: safety@biocryst.com
Estonian: E-post safety@biocryst.com
English: CI = Confidence Interval
Estonian: CI = usaldusvahemik
English: As a precautionary measure, it is preferable to avoid the use of peramivir during pregnancy.
Estonian: Ettevaatusmeetmena on soovitatav peramiviiri kasutamist raseduse ajal vältida.
English: Not known, frequency cannot be estimated from the available data
Estonian: Teadmata, esinemissagedust ei saa hinnata olemasolevate andmete alusel
English: The safety and efficacy of peramivir in children aged under 2 years has not yet been established.
Estonian: Lapsed Peramiviiri ohutus ja efektiivsus alla 2-aastastel lastel ei ole veel tõestatud.
English: Uncomplicated influenza in adults
Estonian: Tüsistusteta gripp täiskasvanutel
English: Chemical and physical in-use stability has been demonstrated for 72 hours at 5 ºC and 25 ºC.
Estonian: Tõestatud on ravimi kasutusaegne keemilis-füüsikaline stabiilsus 72 tunni jooksul temperatuuril 5 ºC ja 25 ºC.
English: Contact your doctor immediately if any of the following side effects occur:
Estonian: Võtke oma arstiga kohe ühendust, kui teil esineb mõni järgmistest kõrvaltoimetest:
English: These medicines prevent the influenza virus from spreading inside the body.
Estonian: Need ravimid ennetavad gripiviiruse levimist organismis.
English: Treatment of an overdose should consist of general supportive measures including monitoring of vital signs and observation of the clinical status of the patient.
Estonian: Üleannustamise ravi peab koosnema üldistest tugimeetmetest, sh elutähtsate funktsioonide seirest ja patsiendi kliinilise seisundi jälgimisest.
English: Adverse Reaction According to Frequency*
Estonian: Kõrvaltoime vastavalt sagedusele*
English: Tell your doctor if you are pregnant or breast-feeding.
Estonian: Öelge oma arstile, kui te olete rase või imetate.
English: There is no specific antidote to treat an overdose of this medicine.
Estonian: Selle ravimi üleannustuse raviks ei ole olemas spetsiifilist antidooti.
English: In general, nephrotoxicity was observed in rabbits, no unexpected toxicity was observed, and no other target organ toxicity was identified in juvenile animals.
Estonian: Üldiselt täheldati küülikutel neerutoksilisust, ootamatut toksilisust ei täheldatud ja noortel loomadel ei leitud muid sihtorganite toksilisuse nähte.
English: • Patients with reduced kidney function may require a reduced dose.
Estonian: • Vähenenud neerufunktsiooniga patsiendid võivad vajada väiksemat annust.
English: What Alpivab looks like and contents of the pack
Estonian: Kuidas Alpivab välja näeb ja pakendi sisu
English: Alpivab is not likely to change your ability to drive and use machines.
Estonian: Ei ole tõenäoline, et Alpivab mõjutaks teie võimet autot juhtida ja masinatega töötada.
English: Haemodialysis initiated at 2 hours after dosing reduced systemic exposure of peramivir by 73 to 81 %.
Estonian: 2 tundi pärast annustamist alustatud hemodialüüs vähendas süsteemset ekspositsiooni peramiviiriga 73%-lt 81%-ni.
English: Based on a population pharmacokinetic analysis, the central volume of distribution was 12.56 L.
Estonian: Populatsiooni farmakokineetika analüüsi järgi oli keskmine jaotusruumala 12,56 l.
English: Neuropsychiatric events
Estonian: Neuropsühhiaatrilised sündmused
English: Each carton contains 3 vials.
Estonian: Igas karbis on 3 viaali.
English: Peramivir is not significantly metabolised in humans.
Estonian: Peramiviir ei metaboliseeru inimorganismis oluliselt.
English: Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000).
Estonian: Sagedused on määratletud järgnevalt: väga sage (≥ 1/10), sage (≥ 1/100 kuni < 1/10), aeg-ajalt (≥ 1/1000 kuni < 1/100), harv (≥ 1/10 000 kuni < 1/1000), väga harv (< 1/10 000).
English: Alpivab is not recommended in children aged under 2 years.
Estonian: Alpivabi ei soovitata kasutada alla 2-aastastel lastel.
English: Symptoms may include confusion, difficulty thinking or hallucinations.
Estonian: Sümptomid võivad olla näiteks segasus, mõtlemisraskused või hallutsinatsioonid.
English: In-vitro binding of peramivir to human plasma proteins is less than 30 %.
Estonian: Peramiviir seondub in vitro inimese plasmaproteiinidega alla 30%.
English: Available data do not support a conclusion that peramivir is effective in patients with influenza B or in patients with complicated influenza.
Estonian: Kasutatavad andmed ei toeta järeldust, et peramiviir on efektiivne B-gripiga või tüsistunud gripiga patsientidel.
English: Alpivab is used to treat adults and children aged from 2 years with influenza that is not severe enough to require hospitalisation.
Estonian: Alpivabi kasutatakse täiskasvanute ja alates 2-aastaste laste raviks sellise gripi korral, mis ei ole nii raske, et vajaks haiglaravi.
English: This is equivalent to 10.6 % of the recommended maximum daily dietary intake of sodium for an adult.
Estonian: See on 10,6% soovitatavast maksimaalsest ööpäevasest toiduga saadavast täiskasvanu naatriumikogusest.
English: Pharmacotherapeutic group: Antivirals for systemic use, neuraminidase inhibitors ATC code: J05AH03
Estonian: Farmakoterapeutiline rühm: viirusvastased ained süsteemseks kasutamiseks, neuraminidaasi inhibiitorid, ATC-kood: J05AH03
English: If any hypersensitivity reaction occurs during infusion of peramivir, the infusion must be stopped immediately and appropriate management should be instituted.
Estonian: Kui peramiviiri infusiooni ajal esineb ülitundlikkusreaktsioon, tuleb infusioon otsekohe peatada ja reaktsiooni asjakohaselt leevendada.
English: Pharmacokinetic sampling in this study was limited to approximately 3 hours after administration of peramivir.
Estonian: Farmakokineetika proovide võtmine piirdus selles uuringus ligikaudu 3 tunniga pärast peramiviiri manustamist.
English: Your doctor will advise on whether you can be given Alpivab during pregnancy, or whether you are to stop breast-feeding for a short period after getting Alpivab.
Estonian: Teie arst annab teile nõu, kas teile tohib Alpivabi raseduse ajal manustada või kas peate imetamise lühikeseks ajaks pärast Alpivabi manustamist katkestama.
English: Rare, may affect up to 1 in 1,000 people • severe skin rash with or without blisters and fever
Estonian: Harva, võib esineda kuni 1 inimesel 1000st • raske nahalööve villide ja palavikuga või ilma
English: Serious bacterial infections may begin with influenza-like symptoms or may coexist with or occur as complications during the course of influenza.
Estonian: Rasked bakterinfektsioonid võivad alata gripisarnaste sümptomitega või võivad esineda koos gripiga või esineda tüsistustena gripi ajal.
English: • if you are allergic to peramivir or any of the other ingredients of this medicine (listed in section
Estonian: • kui olete peramiviiri või selle ravimi mis tahes koostisosade (loetletud lõigus 6) suhtes allergiline.
English: Do not use if seal opening is broken or missing.
Estonian: Ärge viaali kasutage, kui selle kate on katki või puudub.
English: There is no evidence for efficacy of peramivir in any illness caused by agents other than influenza viruses.
Estonian: Puuduvad tõendid peramiviiri efektiivsuse kohta mis tahes haiguste korral, millel on muu põhjus kui gripiviirus.
English: Do not mix or co-infuse Alpivab with other medicines administered into a vein.
Estonian: Ärge segage ega infundeerige Alpivabi koos teiste intravenoossete ravimitega.
English: Adults and adolescents (13 years and older)
Estonian: Täiskasvanud ja noorukid (vähemalt 13 a)
English: The recommended single intravenous dose of peramivir depends on age and body weight as shown in Table 1.
Estonian: Soovituslik ühekordne intravenoosne peramiviiri annus sõltub vanusest ja kehamassist, vt tabel 1.
English: Serum creatinine measurements were used to calculate creatinine clearance (Cockcroft-Gault equation).
Estonian: Kreatiniini kliirensi arvutamiseks kasutati seerumi kreatiniini mõõtmisi (Cockcroft-Gaulti valem).
English: Two-week oral toxicity studies were conducted in juvenile rats and rabbits, and a four-week IV toxicity study was conducted in juvenile rats.
Estonian: Noorte rottide ja küülikutega tehti kahenädalased suukaudse toksilisuse uuringud ning noorte rottidega neljanädalane intravenoosse toksilisuse uuring.
English: What Alpivab contains
Estonian: Mida Alpivab sisaldab
English: There is no preservative or antibacterial agent in the solution.
Estonian: Lahuses ei ole säilitusaineid ega antibakteriaalseid aineid.
English: The European Medicines Agency has deferred the obligation to submit the results of studies with Alpivab in one or more subsets of the paediatric population for the treatment of influenza (see section 4.2 for information on paediatric use).
Estonian: Euroopa Ravimiamet on peatanud kohustuse esitada Alpivabiga läbi viidud uuringute tulemused laste ühe või mitme alarühma kohta gripi ravis (teave lastel kasutamise kohta vt lõik 4.2).
English: In-vitro activity
Estonian: In vitro toime
English: Peramivir has not been shown to prevent such complications.
Estonian: Ei ole tõendatud, et peramiviir ennetaks selliseid tüsistusi.
English: • abnormal behaviour, delirium
Estonian: • käitumishäired, deliirium
English: Children aged from 2 years and <50 kg
Estonian: Vähemalt 2-aastased ja <50 kg lapsed
English: There are no or limited amount of data (less than 300 pregnancies outcomes) from the use of peramivir in pregnant women.
Estonian: Peramiviiri kasutamise kohta rasedatel andmed puuduvad või on piiratud (teada on alla 300 raseduse tulemused).
English: Manufacturer Seqirus Vaccines Limited Gaskill Road, Speke Liverpool
Estonian: Seqirus Vaccines Limited Gaskill Road, Speke Liverpool
English: The contribution of peramivir to these events has not been established.
Estonian: Peramiviiri roll nendes sündmustes ei ole tõestatud.
English: SPECIAL STORAGE CONDITIONS Do not refrigerate or freeze.
Estonian: SÄILITAMISE ERITINGIMUSED Mitte hoida külmkapis ega lasta külmuda.
English: The recommended 600 mg single intravenous dose resulted in shortening of the median time to alleviation of symptoms by 21 hours (see section 5.1).
Estonian: Soovitatava 600 mg ühekordse intravenoosse annuse kasutamisel oli sümptomite leevenemise aja lühenemise mediaanväärtus 21 tundi (vt lõik 5.1).
English: Live attenuated influenza vaccines are not recommended to be used until 48 hours following Alpivab administration due to a theoretical risk that peramivir could reduce the immunogenicity of the vaccine.
Estonian: Elus nõrgestatud gripivaktsiinide kasutamine ei ole soovitatav kuni 48 tundi pärast Alpivabi manustamist teoreetilise riski tõttu, et peramiviir võib vähendada vaktsiini immunogeensust.
English: UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included.
Estonian: AINULAADNE IDENTIFIKAATOR - 2D-vöötkood Lisatud on 2D-vöötkood, mis sisaldab ainulaadset identifikaatorit..
English: The efficacy of peramivir as a single dose treatment for uncomplicated influenza was demonstrated in a single placebo-controlled study conducted in 300 adult patients in Japan during the 2007/2008 influenza season.
Estonian: Peramiviiri efektiivsus ühekordse annusega ravimina tüsistusteta gripi ravis tõendati ühes platseebokontrolliga uuringus, mis toimus Jaapanis gripihooajal 2007/2008 ja kus osales 300 täiskasvanud patsienti.